Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the mechanism of the vasodepressor effect of
endokinin
A/B. An intravenous (IV) bolus of
endokinin
A/B (0.05-0.3 nmol/kg) dose-dependently decreased mean arterial pressure in thiobutabarbital-anesthetized rats. The magnitude of the response was unaffected by IV pretreatment with NG-nitro-L-arginine methyl ester (L-
NAME
, inhibitor of nitric oxide synthase), methylene blue (inhibitor of soluble guanylyl cyclase), indomethacin (cyclooxygenase inhibitor), or tetraethylammonium (TEA, nonspecific K+ channel blocker). L-
NAME
reduced the half-recovery time of the vasodepressor effect of
endokinin
A/B relative to responses in rats pretreated with either saline or norepinephrine, which caused a similar pressor effect as did L-
NAME
. Methylene blue, but not TEA or indomethacin, reduced the recovery time of the vasodepressor effect of
endokinin
A/B. Therefore, the vasodepressor effect of
endokinin
A/B is mediated via the nitric oxide/L-arginine pathway and activation of soluble guanylyl cyclase but not by production of prostanoids or opening of TEA-sensitive K+ channels.
...
PMID:Possible mechanism of the vasodepressor effect of endokinin a/b in anesthetized rats. 1611 30
Rat/mouse
hemokinin
-1 is a mammalian tachykinin peptide whose biological functions have not been well characterized. In the present study, an attempt has been made to investigate the effect and mechanism of action of rat/mouse
hemokinin
-1 on systemic arterial pressure after intravenous (i.v.) injections in anesthetized rats by comparing it with that of substance P. Our data showed that injection of rat/mouse
hemokinin
-1 (0.1, 0.3, 1, 3 and 10 nmol/kg) lowered systemic arterial pressure dose-dependently. This effect was significantly blocked by pretreatment with SR140333 (a selective tachykinin NK1 receptor antagonist) and the NO synthase inhibitor L-
NAME
(Nomega-nitro-L-arginine methyl ester hydrochloride), respectively, but was not affected by bilateral vagotomy or the muscarinic receptor blocker atropine. Compared to rat/mouse
hemokinin
-1, a dose of 3 nmol/kg of substance P caused biphasic changes in systemic arterial pressure (depressor and pressor responses). The results suggest that the mechanism of the depressor response caused by substance P was similar to rat/mouse
hemokinin
-1 in that it was inhibited by SR140333 and L-
NAME
, respectively, but that there was a component of the cardiovascular change induced by rat/mouse
hemokinin
-1 (but not substance P) that was attenuated by SR48968 (a selective tachykinin NK2 receptor antagonist). The depressor response induced by rat/mouse
hemokinin
-1 (i.v.) might be explained primarily by the action on endothelial tachykinin NK1 receptors to release endothelium-derived relaxing factor (NO) and this effect was not affected by vagal components. In addition, rat/mouse
hemokinin
-1 could not induce the pressor response through stimulation of sympathetic ganglion like substance P in anesthetized rats.
...
PMID:Cardiovascular responses to rat/mouse hemokinin-1, a mammalian tachykinin peptide: systemic study in anesthetized rats. 1762 23
The interactions of the chimeric peptide MCRT (YPFPFRTic-NH
2
), based on morphiceptin and neuropeptide FF derivative PFRTic-NH
2
, on the effects of
endokinin
A/B (
EKA/B
) on mean arterial blood pressure of the urethane-anaesthetized rat have been investigated in the absence and presence of tachykinin receptor antagonists, naloxone and NO synthase inhibitors. While MCRT produced dose dependent decreases in mean arterial pressure, in its presence only a small but statistically insignificant decreases in the magnitude and the time course of the depressor effect of
EKA/B
(10nmol/kg) were observed. MCRT had little influence on the depressor effect of
EKA/B
(1 nmol/kg), but strongly potentiated that of
EKA/B
(100nmol/kg). The tachykinin NK
1
receptor antagonist SR140333B (1mg/kg) and the NK
3
antagonist SR142891 (2.79mg/kg) both reduced the hypotensive effects of
EKA/B
and MCRT alone and blocked those of the two peptides in combination. The NK
2
antagonist GR159897 (4mg/kg) partially blocked the depressor effects of
EKA/B
and MCRT alone. Naloxone (2mg/kg) completely blocked the depressor effect of MCTR, but partially blocked that of
EKA/B
. The NO synthase inhibitor l-
NAME
(50mg/kg) partially blocked the depressor effects of
EKA/B
, MCRT, and
EKA/B
+ MCRT. These results could help to better understand the role of tachykinin receptors, opioid receptors and neuropeptide FF receptors in cardiovascular system.
...
PMID:MCRT, a chimeric peptide based on morphiceptin and PFRTic-NH
2
, regulates the depressor effects induced by endokinin A/B. 2778 44
